Group One Trading
ADCT icon

Group One Trading’s ADC Therapeutics ADCT Stock Holding History

Group One Trading’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-100
Closed -$400 – 8002
2025
Q3 		$400 Sell
100
-300
-75% -$946 ﹤0.01% 8169
2025
Q2 		$1.07K Buy
+400
New +$841 ﹤0.01% 7546
2024
Q3 		– Sell
-24,000
Closed -$75.8K – 6557
2024
Q2 		$75.8K Buy
24,000
+4,600
+24% +$18.3K ﹤0.01% 4183
2024
Q1 		$87.1K Buy
19,400
+19,300
+19,300% +$71.2K ﹤0.01% 4258
2023
Q4 		$166 Buy
+100
New +$92 ﹤0.01% 7172
2022
Q2 		– Sell
-200
Closed -$3K – 7714
2022
Q1 		$3K Sell
200
-400
-67% -$6.35K ﹤0.01% 7599
2021
Q4 		$12K Buy
+600
New +$14.5K ﹤0.01% 7256
2021
Q3 		– Sell
-900
Closed -$22K – 8095
2021
Q2 		$22K Buy
900
+600
+200% +$13.9K ﹤0.01% 7116
2021
Q1 		$7K Buy
+300
New +$8.69K ﹤0.01% 7142

Other funds holding ADCT

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Group One Trading's ADCT Position: Q1 2026 in Review

Group One Trading held its ADC Therapeutics (ADCT) position steady in Q1 2026 at 100 shares worth $375. The position accounts for ﹤0.01% of the portfolio, ranked #7345.

Group One Trading first reported a position in ADCT in Q4 2020 and has held it in 13 quarters since. The position peaked at $21.5K in Q1 2024. 118 funds tracked by Wall St. Rank hold ADCT as of Q1 2026.

  • Group One Trading held 100 shares of ADC Therapeutics worth $375 as of Q1 2026.
  • Group One Trading left its ADC Therapeutics share count unchanged in Q1 2026.
  • ADC Therapeutics made up ﹤0.01% of Group One Trading's portfolio in Q1 2026, its #7345 holding.
  • Group One Trading first reported a position in ADC Therapeutics in Q4 2020 and has held it in 13 quarters since.
  • Group One Trading's ADC Therapeutics position peaked at $21.5K in Q1 2024.
  • 118 funds tracked by Wall St. Rank held ADC Therapeutics as of Q1 2026.

Based on Group One Trading's 13F filing for Q1 2026, filed 13 May 2026.